Genomic Heterogeneity of Pancreatic Ductal Adenocarcinoma and Its Clinical Impact
- PMID: 34503261
- PMCID: PMC8430663
- DOI: 10.3390/cancers13174451
Genomic Heterogeneity of Pancreatic Ductal Adenocarcinoma and Its Clinical Impact
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer death due to limited advances in recent years in early diagnosis and personalized therapy capable of overcoming tumor resistance to chemotherapy. In the last decades, significant advances have been achieved in the identification of recurrent genetic and molecular alterations of PDAC including those involving the KRAS, CDKN2A, SMAD4, and TP53 driver genes. Despite these common genetic traits, PDAC are highly heterogeneous tumors at both the inter- and intra-tumoral genomic level, which might contribute to distinct tumor behavior and response to therapy, with variable patient outcomes. Despite this, genetic and genomic data on PDAC has had a limited impact on the clinical management of patients. Integration of genomic data for classification of PDAC into clinically defined entities-i.e., classical vs. squamous subtypes of PDAC-leading to different treatment approaches has the potential for significantly improving patient outcomes. In this review, we summarize current knowledge about the most relevant genomic subtypes of PDAC including the impact of distinct patterns of intra-tumoral genomic heterogeneity on the classification and clinical and therapeutic management of PDAC.
Keywords: chemoresistance; genetic heterogeneity; genomic subtypes; pancreatic ductal adenocarcinoma; prognosis.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8430663/bin/cancers-13-04451-g001.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8430663/bin/cancers-13-04451-g002.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8430663/bin/cancers-13-04451-g003.gif)
Similar articles
-
Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma.Cancer. 2020 Sep 1;126(17):3939-3949. doi: 10.1002/cncr.33038. Epub 2020 Jun 23. Cancer. 2020. PMID: 32573775 Free PMC article.
-
Recent advances in precision medicine for pancreatic ductal adenocarcinoma.Ann Gastroenterol Surg. 2021 Feb 3;5(4):457-466. doi: 10.1002/ags3.12436. eCollection 2021 Jul. Ann Gastroenterol Surg. 2021. PMID: 34337294 Free PMC article. Review.
-
Clinical and Genomic Characterization of Pancreatic Ductal Adenocarcinoma with Signet-Ring/Poorly Cohesive Cells.Mod Pathol. 2023 Sep;36(9):100251. doi: 10.1016/j.modpat.2023.100251. Epub 2023 Jun 22. Mod Pathol. 2023. PMID: 37355152
-
Genetic Alterations of Periampullary and Pancreatic Ductal Adenocarcinoma: An Overview.Curr Genomics. 2018 Sep;19(6):444-463. doi: 10.2174/1389202919666180221160753. Curr Genomics. 2018. PMID: 30258276 Free PMC article. Review.
-
Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes.BMC Cancer. 2018 May 29;18(1):603. doi: 10.1186/s12885-018-4546-8. BMC Cancer. 2018. PMID: 29843660 Free PMC article.
Cited by
-
A Curated Cell Life Imaging Dataset of Immune-enriched Pancreatic Cancer Organoids with Pre-trained AI Models.Sci Data. 2024 Jul 24;11(1):820. doi: 10.1038/s41597-024-03631-3. Sci Data. 2024. PMID: 39048591 Free PMC article.
-
Single-cell transcriptome reveals the heterogeneity of malignant ductal cells and the prognostic value of REG4 and SPINK1 in primary pancreatic ductal adenocarcinoma.PeerJ. 2024 May 28;12:e17350. doi: 10.7717/peerj.17350. eCollection 2024. PeerJ. 2024. PMID: 38827297 Free PMC article.
-
PD-L1 expression in pancreaticobiliary adenosquamous carcinoma: a single-institution case series.J Gastrointest Oncol. 2024 Apr 30;15(2):768-779. doi: 10.21037/jgo-24-9. Epub 2024 Apr 25. J Gastrointest Oncol. 2024. PMID: 38756636 Free PMC article.
-
Functional and Potential Therapeutic Implication of MicroRNAs in Pancreatic Cancer.Int J Mol Sci. 2023 Dec 15;24(24):17523. doi: 10.3390/ijms242417523. Int J Mol Sci. 2023. PMID: 38139352 Free PMC article. Review.
-
AUM302, a novel triple kinase PIM/PI3K/mTOR inhibitor, is a potent in vitro pancreatic cancer growth inhibitor.PLoS One. 2023 Nov 9;18(11):e0294065. doi: 10.1371/journal.pone.0294065. eCollection 2023. PLoS One. 2023. PMID: 37943821 Free PMC article.
References
-
- De Wilde R.F., Hruban R.H., Maitra A., Offerhaus G.J. Reporting precursors to invasive pancreatic cancer: Pancreatic intraepithelial neoplasia, intraductal neoplasms and mucinous cystic neoplasm. Diagn. Histopathol. 2012;18:17–30. doi: 10.1016/j.mpdhp.2011.10.012. - DOI
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous